Discourage Using PPIs With New Hep C Med Epclusa

September 2016

Please see the October 2016 FDA advisory about the risk of Hepatitis B reactivation in some patients being treated for Hepatitis C.

Epclusa (ep-KLOO-suh, sofosbuvir/velpatasvir) will further simplify hepatitis C treatment.

So far, other recent hep C meds (Harvoni, etc) can only be used for certain hep C genotypes...and duration can vary.

But Epclusa is a one-tab, once-daily med that can be used for ANY hep C genotype...and patients use just a 12-week course.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote